SCHEMBL14724203

SCHEMBL14724203

NCCCN1c2ccccc2Sc2ccc(C(F)(F)F)cc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 5/20 0.72
MAPK1 P28482 5/20 0.72
CYP1A2 P05177 3/20 0.72
ABCB1 P08183 3/20 0.72
HTR1A P08908 3/20 0.72
ADRA2A P08913 3/20 0.72
ADORA3 P0DMS8 3/20 0.72
CYP2D6 P10635 3/20 0.72
CHRM1 P11229 3/20 0.72
DRD1 P21728 3/20 0.72
SLC6A2 P23975 3/20 0.72
SLC6A4 P31645 3/20 0.72
ADRA1A P35348 3/20 0.72
DRD3 P35462 3/20 0.72
THPO P40225 3/20 0.72
MTOR P42345 3/20 0.72
SLC6A3 Q01959 3/20 0.72
KCNH2 Q12809 3/20 0.72
ABCB11 O95342 3/20 0.72
NPC1 O15118 2/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7746782 0.95 FPR2 (0.69) TP53MAPK1CYP1A2ABCB1HTR1A
SCHEMBL10168752 0.92 FPR2 (0.82) TP53MAPK1CYP1A2ABCB1HTR1A
SCHEMBL561009 0.87 FPR2 (0.82) TP53MAPK1CYP1A2ABCB1HTR1A
SCHEMBL14809956 0.87 TP53 (0.72) TP53MAPK1CYP1A2ABCB1HTR1A
SCHEMBL561399 0.87 LMNA (0.75) TP53MAPK1CYP1A2ABCB1HTR1A
SCHEMBL24439717 0.87 FPR2 (0.78) TP53MAPK1CYP1A2ABCB1HTR1A
SCHEMBL10168007 0.86 FPR2 (0.72) TP53MAPK1CYP1A2ABCB1HTR1A
SCHEMBL15805949 0.86 TP53 (0.55) TP53MAPK1CYP1A2ABCB1HTR1A
SCHEMBL561173 0.86 LMNA (0.73) TP53MAPK1CYP1A2ABCB1HTR1A
SCHEMBL16169647 0.85 TP53 (0.57) TP53MAPK1CYP1A2ABCB1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034193-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF CAMP4 THERAPEUTICS CORPORATION 2025-01-30 US disclosed
US-12145963-B2 Phenothiazine derivatives and uses thereof CAMP4 THERAPEUTICS CORPORATION (US) 2024-11-19 US disclosed
US-20240139178-A1 METHOD FOR MANUFACTURING COMPOSITION FOR COMPOSITION FOR INCREASING COGNITIVE FUNCTION AMYLOID SOLUTION INC. (KR) 2024-05-02 US disclosed
US-20230257410-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF CAMP4 THERAPEUTICS CORPORATION 2023-08-17 US disclosed
US-20230257410-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF CAMP4 THERAPEUTICS CORPORATION 2023-08-17 US disclosed
US-20230257410-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF CAMP4 THERAPEUTICS CORPORATION 2023-08-17 US disclosed
US-11542290-B2 Phenothiazine derivatives and uses thereof CAMP4 THERAPEUTICS CORPORATION (US) 2023-01-03 US disclosed
US-11542290-B2 Phenothiazine derivatives and uses thereof CAMP4 THERAPEUTICS CORPORATION (US) 2023-01-03 US disclosed
EP-3888655-A1 THERAPEUTIC COMPOSITION AND TREATMENT METHOD FOR AMYLOID NEUROLOGICAL DISEASES Amyloid Solution Inc. (KR) 2021-10-06 EP disclosed
US-20210061837-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF CAMP4 THERAPEUTICS CORPORATION 2021-03-04 US disclosed
US-20200330474-A1 COMPOSITION AND METHOD FOR TREATMENT OF AMYLOID CRANIAL NEUROPATHY AMYLOID SOLUTION INC. (KR) 2020-10-22 US disclosed
WO-2020111824-A1 THERAPEUTIC COMPOSITION AND TREATMENT METHOD FOR AMYLOID NEUROLOGICAL DISEASES 아밀로이드솔루션 주식회사 2020-06-04 WO disclosed
WO-2019195789-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF CAMP4 THERAPEUTICS CORPORATION (US) 2019-10-10 WO disclosed
US-20140308317-A1 Polymeric Compounds And Methods Of Making And Using The Same CELLCEUTIX CORPORATION (US) 2014-10-16 US disclosed
US-20140308317-A1 Polymeric Compounds And Methods Of Making And Using The Same CELLCEUTIX CORPORATION (US) 2014-10-16 US disclosed
US-8383617-B2 Treatment of protein aggregation diseases PAD PHARMA LIMITED (GB) 2013-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200330474-A1 COMPOSITION AND METHOD FOR TREATMENT OF AMYLOID CRANIAL NEUROPATHY MAPT, PSEN1, PYGB TP53 3042/4885MAPK1 1395/4885CYP1A2 4438/4885
US-20210061837-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF RPLP2, RPS2, RPLP1 TP53 1987/4885MAPK1 3288/4885CYP1A2 1724/4885
US-20230257410-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF RPLP2, RPS2, RPLP1 TP53 1987/4885MAPK1 3288/4885CYP1A2 1724/4885
US-20240139178-A1 METHOD FOR MANUFACTURING COMPOSITION FOR COMPOSITION FOR INCREASING COGNITIVE FUNCTION PSEN2, PSEN1, NEFM TP53 1147/4885MAPK1 3697/4885CYP1A2 928/4885
US-12145963-B2 Phenothiazine derivatives and uses thereof RPLP2, RPS2, RPLP1 TP53 1987/4885MAPK1 3288/4885CYP1A2 1724/4885
US-20250034193-A1 PHENOTHIAZINE DERIVATIVES AND USES THEREOF RPLP2, RPS2, RPLP1 TP53 1987/4885MAPK1 3288/4885CYP1A2 1724/4885
US-11542290-B2 Phenothiazine derivatives and uses thereof RPLP2, RPS2, RPLP1 TP53 1987/4885MAPK1 3288/4885CYP1A2 1724/4885
US-20140308317-A1 Polymeric Compounds And Methods Of Making And Using The Same ALG1, CD44, MUC1 TP53 578/4885MAPK1 662/4885CYP1A2 4240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.